Browsing Tag
Agios Pharmaceuticals
7 posts
Agios shakes up sickle cell therapy landscape with mixed but promising RISE UP phase 3 data for mitapivat
Find out how Agios’ mixed but promising RISE UP phase 3 data for mitapivat could reshape sickle cell treatment and influence regulatory decisions.
Inhibrx Biosciences’ Ozekibart sets new benchmark in rare bone cancer treatment and advances toward 2026 BLA filing
Find out how Inhibrx Biosciences’ Ozekibart delivered breakthrough results in chondrosarcoma and is advancing toward a 2026 BLA filing—read more now!
Agios Pharmaceuticals’ mitapivat shows significant promise in Phase 3 ENERGIZE study
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a pioneer in cellular metabolism and pyruvate kinase (PK) activation therapies, unveiled detailed…
Agios Pharmaceuticals’ mitapivat meets primary endpoint in Phase 3 thalassemia trial
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative therapies in cellular metabolism and pyruvate kinase (PK) activation,…
Agios Pharmaceuticals gets PYRUKYND FDA approval for hemolytic anemia
Agios Pharmaceuticals has secured approval for PYRUKYND (mitapivat) from the US Food and Drug Administration (FDA) for the…
FDA approves Agios Pharmaceuticals’ Tibsovo for targeted acute myeloid leukemia treatment
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals for Tibsovo (ivosidenib), designed for…
FDA approves Agios Pharmaceuticals’ TIBSOVO for acute myeloid leukemia
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals’ TIBSOVO (ivosidenib) for the treatment…